So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. They are ranked below in descending order as to their performances MTD (month-to-date).
- Mind Medicine (MNMD): down 2.3% MTD
- is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Read: MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
- Seelos (SEEL): down 4.6% MTD
- focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
- Read: Description Of Diseases Seelos Therapeutics Is Focused On
- Compass Pathways (CMPS): down 10.8% MTD
- focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Read: COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
- Incannex Healthcare (IXHL): down 11.3% MTD
- is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Read: Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
- GH Research (GHRS): down 15.5% MTD
- is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nickname, “The Toad”.
- Atai (ATAI): down 18.4% MTD
- focused on the use of ketamine*, DMT* and ibogaine*. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Read: atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.
Summary
The munKNEE Psychedelic Drug Stocks Index is down 11.9% MTD but is up 13.6% YTD.
If you are interested in this category, consider the AdvisorShares Psychedelic ETF (PSIL), which consists of 23 such stocks (of which the majority have market capitalizations of less than $50M). It is down 8.2% MTD and is now down 3.2% YTD.
More By This Author:
Cronos Brands' Q2 Financials Show Major Reduction In Net Loss
Curaleaf Q2 Financials Report 31% Increase In Net Loss
Canopy Growth Q1 Financial Report: Cannabis Revenue Down 26%
Disclosure: None
Visit munKNEE.com and register to receive our free Market Intelligence Report newsletter ...
more